RxDoctor Payments Data

Lakshmi Nadiminti, DO

Neurology · Ny, NYNPI 1801055660

Payments from drug & device makers

$495in general payments, 2019–2025

Across 27 payments — averaging $18.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$152
  • AbbVie$65
  • Biohaven Pharmaceuticals, Inc.$65
  • UCB, Inc.$58
  • EMD Serono, Inc.$41
  • Upsher-smith Laboratories LLC$35
  • plus $79 from 5 others

What the payments were for

  • Food & beverage$48297%
  • Education$133%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$495 in reported general payments places this provider in the 35th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$69,266
Medicare patients
226
Services billed
450

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RebifInterferon Beta-1a/Albumin12$121,552
Nurtec OdtRimegepant Sulfate29$29,395
UbrelvyUbrogepant15$16,994
Rufinamide12$11,919
Aimovig AutoinjectorErenumab-Aooe13$9,672
Levetiracetam134$5,466
Gabapentin133$4,948
Memantine Hcl182$4,724
Divalproex Sodium25$4,160
Lacosamide43$3,887
Lamotrigine175$2,802
Oxcarbazepine29$2,799
AmantadineAmantadine Hcl34$2,786
Carbidopa-LevodopaCarbidopa/Levodopa88$2,254
Topiramate80$2,114

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
EMD Serono, Inc.Rebif$41$121,55212 claims
PfizerNurtec Odt, Dilantin$152$29,70045 claims
AbbVieUbrelvy$65$16,99415 claims
Upsher-smith Laboratories LLCTopiramate$35$2,11480 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,623 neurology providers in New York.

Other neurology in Ny

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →